MXPA05013281A - Composiciones farmaceuticas de atorvastatina. - Google Patents
Composiciones farmaceuticas de atorvastatina.Info
- Publication number
- MXPA05013281A MXPA05013281A MXPA05013281A MXPA05013281A MXPA05013281A MX PA05013281 A MXPA05013281 A MX PA05013281A MX PA05013281 A MXPA05013281 A MX PA05013281A MX PA05013281 A MXPA05013281 A MX PA05013281A MX PA05013281 A MXPA05013281 A MX PA05013281A
- Authority
- MX
- Mexico
- Prior art keywords
- atorvastatin
- compositions
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Abstract
Una composicion farmaceutica granulada en humedo que comprende atorvastatina o una de sus sales farmaceuticamente aceptables con menos de aproximadamente 5% en peso de un aditivo constituido por una sal de metal alcalino-terreo con un desintegrante, que proporciona la atorvastatina con no mas de aproximadamente 3% de lactona de atorvastatina, basada en la relacion del area del pico de lactona comparada con las areas integradas de todos los picos relacionados con el farmaco, asi como dicha composicion farmaceutica granulada en humedo que comprende atorvastatina o una de sus sales farmaceuticamente aceptables en combinacion con al menos otro farmaco activo, metodos para preparar dichas composiciones, kits para contener dichas composiciones, y un metodo de tratar hipercolesterolemia y/o hiperlipidemia, osteoporosis, hiperplasia prostatica benigna (BPH), y la enfermedad de Alzheimer que comprende una cantidad terapeuticamente eficaz de las composiciones farmaceuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47811903P | 2003-06-12 | 2003-06-12 | |
| PCT/IB2004/001862 WO2004110431A1 (en) | 2003-06-12 | 2004-06-01 | Stable compositions of atorvastatin prepared with wet granulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05013281A true MXPA05013281A (es) | 2006-03-09 |
Family
ID=33551806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05013281A MXPA05013281A (es) | 2003-06-12 | 2004-06-01 | Composiciones farmaceuticas de atorvastatina. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1635814A1 (es) |
| JP (1) | JP2006527260A (es) |
| KR (1) | KR100814218B1 (es) |
| CN (1) | CN100434069C (es) |
| AR (1) | AR044774A1 (es) |
| AU (1) | AU2004246868B2 (es) |
| BR (1) | BRPI0411344A (es) |
| CA (1) | CA2465565A1 (es) |
| CO (1) | CO5650230A2 (es) |
| MX (1) | MXPA05013281A (es) |
| NO (1) | NO20060022L (es) |
| NZ (1) | NZ543337A (es) |
| RU (1) | RU2332211C2 (es) |
| TW (1) | TW200503690A (es) |
| WO (1) | WO2004110431A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| GB0613925D0 (en) | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
| EP2170294A1 (en) * | 2007-06-25 | 2010-04-07 | Pharmathen S.A. | Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof |
| KR20100125346A (ko) * | 2008-02-27 | 2010-11-30 | 토멘 메디칼 아게 | 임플란트 및 이의 제조 방법 |
| US20100209495A1 (en) * | 2008-09-17 | 2010-08-19 | Mylan Laboratories, Inc. | Granulates, process for preparing them and pharmaceutical products containing them |
| RU2404767C1 (ru) * | 2009-08-11 | 2010-11-27 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма, обладающая гиполипидемической и гипохолестеринемической активностью, и способ ее получения |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| EP2779999A2 (en) | 2011-11-15 | 2014-09-24 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising atorvastatin and glimepiride |
| SMT201800590T1 (it) * | 2012-11-02 | 2019-01-11 | Vertex Pharma | Composizioni farmaceutiche per il trattamento di malattie mediate da cftr |
| CN104069078B (zh) * | 2014-05-22 | 2019-06-11 | 西藏九瑞健康股份有限公司 | 阿托伐他汀钙药物组合物及其制备方法 |
| SG10201900648SA (en) * | 2014-07-25 | 2019-02-27 | Novartis Ag | Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide |
| KR101658350B1 (ko) * | 2015-02-06 | 2016-09-30 | 경성대학교 산학협력단 | 고지혈증 치료에 유용한 약학 조성물 |
| CN107427462B (zh) * | 2015-03-12 | 2023-08-29 | 杜邦营养美国有限公司 | 固态分散体 |
| TW201735928A (zh) | 2016-03-31 | 2017-10-16 | 大日本住友製藥股份有限公司 | 溶出性優異之口服製劑 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG45369A1 (en) * | 1993-01-19 | 1998-10-16 | Warner Lambert Co | Stable oral ci-981 formulation and process of preparing same |
| JPH06242003A (ja) * | 1993-02-12 | 1994-09-02 | Nkk Corp | 鉄鋼中のアルミナの粒度測定方法 |
| JP3014040B2 (ja) * | 1996-10-30 | 2000-02-28 | 信久 川野 | 食物繊維パン及びその製造法 |
| ES2372682T5 (es) * | 2000-04-10 | 2014-10-30 | Teva Pharmaceutical Industries Ltd. | Composiciones farmacéuticas estables que contienen ácidos 7-sustituidos-3,5-dihidroxiheptanoicos o ácidos 7-sustituidos-3,5-dihidroxiheptenoicos |
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| EP1226818A1 (en) * | 2001-01-26 | 2002-07-31 | Pfizer Products Inc. | Pharmaceutical dosage forms with enhanced cohesive and compressibility properties |
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| EP1291017A3 (en) * | 2001-09-10 | 2003-07-02 | Warner-Lambert Company | Use of statins to inhibit formation of osteoclasts |
-
2004
- 2004-04-29 CA CA002465565A patent/CA2465565A1/en not_active Abandoned
- 2004-06-01 JP JP2006516512A patent/JP2006527260A/ja active Pending
- 2004-06-01 MX MXPA05013281A patent/MXPA05013281A/es not_active Application Discontinuation
- 2004-06-01 WO PCT/IB2004/001862 patent/WO2004110431A1/en not_active Ceased
- 2004-06-01 BR BRPI0411344-6A patent/BRPI0411344A/pt not_active IP Right Cessation
- 2004-06-01 CN CNB2004800163910A patent/CN100434069C/zh not_active Expired - Fee Related
- 2004-06-01 AU AU2004246868A patent/AU2004246868B2/en not_active Ceased
- 2004-06-01 KR KR1020057023669A patent/KR100814218B1/ko not_active Expired - Fee Related
- 2004-06-01 NZ NZ543337A patent/NZ543337A/en unknown
- 2004-06-01 RU RU2005136745/15A patent/RU2332211C2/ru not_active IP Right Cessation
- 2004-06-01 EP EP04735614A patent/EP1635814A1/en not_active Withdrawn
- 2004-06-10 AR ARP040102008A patent/AR044774A1/es unknown
- 2004-06-11 TW TW093116894A patent/TW200503690A/zh unknown
-
2005
- 2005-12-09 CO CO05124741A patent/CO5650230A2/es not_active Application Discontinuation
-
2006
- 2006-01-03 NO NO20060022A patent/NO20060022L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1635814A1 (en) | 2006-03-22 |
| WO2004110431A1 (en) | 2004-12-23 |
| CN100434069C (zh) | 2008-11-19 |
| RU2005136745A (ru) | 2006-07-27 |
| CA2465565A1 (en) | 2004-12-12 |
| NZ543337A (en) | 2008-03-28 |
| CO5650230A2 (es) | 2006-06-30 |
| TW200503690A (en) | 2005-02-01 |
| BRPI0411344A (pt) | 2006-07-11 |
| AU2004246868A1 (en) | 2004-12-23 |
| AU2004246868B2 (en) | 2008-01-17 |
| KR20060020666A (ko) | 2006-03-06 |
| JP2006527260A (ja) | 2006-11-30 |
| AR044774A1 (es) | 2005-10-05 |
| RU2332211C2 (ru) | 2008-08-27 |
| CN1805741A (zh) | 2006-07-19 |
| NO20060022L (no) | 2006-01-03 |
| KR100814218B1 (ko) | 2008-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200509905A (en) | Pharmaceutical compositions of atorvastatin | |
| MXPA05013281A (es) | Composiciones farmaceuticas de atorvastatina. | |
| EP2305251A3 (en) | Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder | |
| TW200503689A (en) | Pharmaceutical compositions of atorvastatin | |
| TNSN01130A1 (fr) | Formulations a liberation prolongee pour des secretagogues d'hormone de croissance | |
| WO2005034908A3 (en) | A solid dosage form comprising a fibrate and a statin | |
| CA2366702A1 (en) | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents | |
| NZ524138A (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
| WO2007000778A3 (en) | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof | |
| ATE260658T1 (de) | Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen | |
| NZ502449A (en) | Tricyclic vasopressin agonists and their pharmaceutical use | |
| WO2004041755A3 (en) | Quinazolinone compounds as calcilytics | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| CA2378613A1 (en) | Selective iglur5 receptor antagonists for the treatment of migraine | |
| WO2005032470A3 (en) | Compositions and methods for treating burns | |
| WO2003045319A3 (en) | Targeted therapeutics and uses thereof | |
| YU19301A (sh) | Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze | |
| GB2405336A (en) | Cholinesterase inhibitors to prevent injuries caused by chemicals | |
| CA2378428A1 (en) | Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes | |
| WO2006118948A3 (en) | Therapeutic compositions | |
| EA200100871A1 (ru) | Кристаллическая форма эплеренона, обладающая повышенной скоростью растворения | |
| MXPA03010672A (es) | Composicion para el tratamiento regenerativo de enfermedades del cartilago. | |
| WO2006115770A3 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
| DE69911017D1 (en) | Arylsulfonanilid-phosphate | |
| MXPA05008711A (es) | Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |